Vortioxetine for the treatment of major depressive disorder:a rapid health technology assessment
Objective To evaluate the efficacy,safety and economy of vortioxetine in the treatment of major depressive disorder based on rapid health technology assessment(HTA),providing reference for clinical medication and health policy de-cisions.Methods PubMed,Embase,the Cochrane Library,CNKI,Wanfang Data,SinoMed,and HTA institutions were sys-tematically retrieved.Two researchers independently screened the literature,extracted data,evaluated quality,and performed descriptive analysis.Results Totally 28 studies involving 3 HTA reports,19 systematic review/meta analyses and 6 pharmaco-economic evaluations were finally included,qualities of which were medium or high.Compared with placebo,vortioxetine improved response rate and remission rate,and reduced depressive symptoms and cognitive function-related scale scores.Vor-tioxetine had no difference in efficacy compared with selective serotonin reuptake inhibitors,serotonin-norepinephrine reup-take inhibitors,and agomelatine.The overall adverse reaction incidence of vortioxetine was low,mainly including gastrointes-tinal symptoms such as nausea.For major depressive disorder patients who had responded inadequately to one or two antide-pressants,choosing vortioxetine as a switch therapy was more cost-effective.Conclusion Vortioxetine has good efficacy,and safety but higher cost,which is more cost-effective for second-line or third-line treatment of major depressive disorder.
NETL
NSTL
万方数据
